BlackRock, Inc. ownership in 2B30 / Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.

DE ˙ DB ˙ US98422E1038

5,20 € ↑0,22 (4,40%)

2026-06-05
PREZZO DELLE AZIONI

Security	DE:2B30 / Xeris Biopharma Holdings, Inc.
Institution	BlackRock, Inc.
Latest Disclosed Ownership	10,011,391 shares
Ownership	7.20%

2024-01-26 - BlackRock, Inc. has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 10,011,391 shares of Xeris Biopharma Holdings, Inc. (DE:2B30). This represents 7.2 percent ownership of the company. In their previous filing dated 2021-07-12 , BlackRock, Inc. had reported owning 1,684,166 shares, indicating an increase of 494.44 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2024-01-26	2024-01-26	13G	1,684,166	10,011,391	494.44	7.20	188.00
2021-07-12	2021-07-12	13G	3,647,218	1,684,166	-53.82	2.50	-66.22
2021-02-01	2021-02-01	13G/A	2,196,747	3,647,218	66.03	7.40	-8.64
2020-02-07	2020-02-07	13G		2,196,747		8.10

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-13	2026-03-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	12,945,785	306,467	2.42	75,086	-24.32	0.0001
2026-02-12	2025-12-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	12,639,318	711,619	5.97	99,219	2.19	0.0017
2025-11-12	2025-09-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	11,927,699	391,378	3.39	97,091	80.22	0.0017
2025-08-12	2025-06-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	11,536,321	741,720	6.87	53,875	-9.09	0.0010
2025-05-02	2025-03-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	10,794,601	-26,527	-0.25	59,262	61.55	0.0012
2025-02-07	2024-12-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	10,821,128	87,097	0.81	36,684	19.91	0.0007
2024-11-13	2024-09-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	10,734,031	401,953	3.89	30,592	31.59	0.0006
2024-08-13	2024-06-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	10,332,078	371,572	3.73	23,247	5.61	0.0005
2024-05-10	2024-03-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	9,960,506	-50,885	-0.51	22,013	-6.44	0.0005
2024-02-13	2023-12-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	10,011,391	637,149	6.80	23,527	34.93	0.0006
2023-11-13	2023-09-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	9,374,242	39,646	0.42	17,436	-28.70	0.0005
2023-08-11	2023-06-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	9,334,596	921,416	10.95	24,457	78.34	0.0007
2023-05-12	2023-03-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	8,413,180	-163,033	-1.90	13,713	20.23	0.0004
2023-02-13	2022-12-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	8,576,213	347,585	4.22	11,406	-11.15	0.0004
2022-11-14	2022-09-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	8,228,628	221,834	2.77	12,838	4.11	0.0004
2022-08-12	2022-06-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	8,006,794	6,011,915	301.37	12,331	141.45	0.0004
2022-05-12	2022-03-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	1,994,879	199,366	11.10	5,107	-2.93	0.0001
2022-02-10	2021-12-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	1,795,513	1,795,513		5,261		0.0001

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.